Hamaad Ali, Kaeng Lee W, Lip Gregory Y H, MacFadyen Robert J
University Department of Medicine, City Hospital, Dudley Road, Birmingham, England, UK.
Cardiovasc Drugs Ther. 2006 Oct;20(5):359-64. doi: 10.1007/s10557-006-0295-z.
To determine the effects of n3-PUFA supplementation, in the dose used in the GISSI-Prevenzione study, on indices of heart rate variability (HRV) in patients following myocardial infarction (AMI).
Open label randomised single blind controlled trial. Thirty eight patients post AMI, stable on standard secondary prevention drug therapy were single blind randomised to receive either Omacor 1 g/day (n = 21) or usual care (n = 17). HRV indices (time and frequency-domain) were measured at baseline and following 3 months of treatment.
At baseline there were no significant differences in clinical, biochemical or HRV indices between patient groups. After 3 months therapy there were no observed changes in measured HRV indices in either the Omacor supplemented or 'usual care' groups.
Three month supplementation of omega 3 PUFA (Omacor) 1 g/day has no effect on HRV is patients post AMI.
确定按照GISSI-Prevenzione研究中所使用的剂量补充n3-多不饱和脂肪酸（n3-PUFA）对心肌梗死（AMI）患者心率变异性（HRV）指标的影响。
开放标签随机单盲对照试验。38例AMI后患者，在标准二级预防药物治疗下病情稳定，单盲随机分为两组，分别接受每日1克Omacor治疗（n = 21）或常规治疗（n = 17）。在基线期及治疗3个月后测量HRV指标（时域和频域）。
基线期，两组患者在临床、生化或HRV指标方面无显著差异。治疗3个月后，补充Omacor组和“常规治疗”组所测HRV指标均未观察到变化。
对AMI后患者每日补充1克ω-3多不饱和脂肪酸（Omacor）3个月对HRV无影响。
Zotero 插件